Temedica, the company behind Permea, is a Munich, Germany-based digital health and health insights company with the mission to bring the patient into the center of healthcare. The company develops state-of-the-art digital patient companions for complex, chronic conditions. These apps support patients with personalized guidance and help them navigate healthcare systems by considering their individual needs. Through direct and long-term interaction with patients, Temedica generates unique and previously unknown real-world evidence about disease progression and the individual effectiveness of therapies.
Temedica is an expert in the personalized support of patients and in compiling, structuring and analyzing health data. Its data analytics platform Permea is designed to enable unique insights along the entire healthcare value chain and patient journey.
Experts Advisory Board
Temedica is supported by a consortium of renowned investors with longstanding track-records in the biopharmaceutical industry, including the founding investors of BioNTech.